ArticleJournal of ovarian research2025
Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention.Journal of ovarian research · 2026Review
- Diagnostic and prognostic biomarkers associated with histotype in advanced epithelial ovarian cancer.Scientific reports · 2025Article
- Molecular Pathology of Ovarian Endometrioid Carcinoma: A Review.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEpithelial ovarian cancer (EOC) is a deadly and heterogenous disease comprising five major histotypes: clear cell carcinoma (CCC), endometrioid carcinoma (EC), low- and high-grade serous carcinoma (LGSC, HGSC), and mucinous carcinoma (MC). Despite this heterogeneity, EOC is often treated as a homogenous disease, and reliable screening tests are lacking. Although progress has been made, there is a pressing need for biomarkers to refine patient stratification, guide treatment, and improve outcomes. Here, we elucidated the relationship between DNA methylation and gene expression patterns in EOC to identify histotype-specific biomarkers.
methodsDifferential DNA methylation and gene expression analyses were performed for 86 early-stage EOC samples after histopathological reclassification stratified by histotype. The correlation between DNA methylation and gene expression was examined, and histotype-specific biomarkers were identified. Hierarchical clustering and predictive machine learning modeling were employed to assess the performance of the histotype-specific biomarkers using four external cohorts.
resultsEOC histotypes exhibited distinct epigenetic, transcriptional, and functional profiles, with candidate histotype-specific biomarkers such as CTSE and VCAN effectively distinguishing CCC, HGSC, and MC on the transcriptional level. Gene expression for the candidate biomarkers was found to be reproducible across external cohorts, with histotype-specific differences remaining homogenous.
conclusionsThis study identified promising histotype-specific biomarkers for EOC using integrative transcriptomic and epigenomic analysis. Furthermore, these findings indicate that additional stratification or potential reclassification of the EC histotype is warranted in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.